Conference Coverage

What predicts successful weight loss maintenance in WeightWatchers?


 

FROM OBESITY WEEK® 2023

Study design and findings

Between 2019 and 2020, WeightWatchers invited adult members who had maintained weight loss of at least 9.1 kg (20 lb) for at least 1 year to participate in this study.

Of 7,025 participants who entered the study, 4,004 individuals (57%) who did not complete the 1-year questionnaires and others with implausible weight were excluded, leaving a final sample of 2,843 participants.

Most participants were women (92%), non-Hispanic White (95%), married (92%), and college educated. They had a mean age of 56 years.

On average, the participants had a body mass index (BMI) of 35.9 kg/m2 (grade 2 obesity) at the start of the WeightWatchers program and a BMI of 26.7 when they entered the current study.

At the 1-year follow-up, 57% of the participants had maintained the same weight (within 2.3 kg) as when they enrolled in the study, and 43% had gained ≥ 2.3 kg.

On average, the weight-loss maintainers had gained 0.4 kg (0.88 lb). The weight gainers had gained 7.2 kg (15.9 lb) but were still 19.1 kg (42.1 lb) below the weight they had when they started the WeightWatchers program.

At baseline, compared with the weight gainers, the weight-loss maintainers were on average older (58 vs. 52 years), had a lower initial BMI (26 vs. 28), and had longer duration of weight loss maintenance (4 vs. 3 years).

At 1 year, those who had maintained their weight loss had greater self-monitoring, psychological coping, physical activity strategies, dietary choice strategies, and eating and physical activity habits, and they had less eating initiation in the absence of hunger.

They also had less disinhibition, more willingness to ignore cravings and accept food urges, more future orientation, more mindfulness, more positive body image and body satisfaction, better general health and mental health, and less bodily pain.

This research was supported by a grant to Dr. Phelan from WeightWatchers (WW) International, and three study authors are employees and shareholders of the company. Dr. Jensen discloses consulting for Biohaven Pharmaceuticals and for Seattle Gummy Co.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

The new word in liver disease: The story behind NAFLD’s rebranding as MASLD
Clinician Reviews
Are they ‘antiobesity medications’ or ‘weight-loss drugs’?
Clinician Reviews
Roflumilast side effect benefits patients with psoriasis and overweight/obesity
Clinician Reviews
New ‘twincretin’ pemvidutide: Another option for obesity
Clinician Reviews
Metformin, weight management to stop type 2 diabetes in kids
Clinician Reviews
Scientists find the ‘on’ switch for energy-burning brown fat
Clinician Reviews
Addressing obesity bias in health care
Clinician Reviews
Taking a new obesity drug and birth control pills? Be careful
Clinician Reviews
Antidepressants ‘don’t blunt’ semaglutide and weight loss
Clinician Reviews
ESG yields significant, sustained weight loss across obesity classes
Clinician Reviews